

## Supplementary information

### **AP4 suppresses DNA damage, chromosomal instability and senescence via inducing *MDC1/Mediator of DNA damage Checkpoint 1* and repressing *MIR22HG/miR-22-3p***

**Chou *et al.***

#### **List of contents:**

**Additional file 1: Fig. S1:** *AP4* inactivation induces senescence and apoptosis in CRC cells.

**Additional file 2: Fig. S2:** *AP4* inactivation induces DNA damage in CRC cells.

**Additional file 3: Fig. S3:** *AP4* directly represses *MIR22HG*.

**Additional file 4: Fig. S4:** *MDC1* is directly and indirectly regulated by *AP4*.

**Additional file 5: Fig. S5:** *MDC1* mediates effects of *AP4* on DNA damage and senescence.

**Additional file 6: Fig. S6:** *MDC1* mediates effects of *AP4* on chromosomal instability and HR.

**Additional file 7: Fig. S7:** *AP4* confers resistance towards Etoposide via *MDC1*.

**Additional file 8: Fig. S8:** *AP4* confers resistance towards 5-FU via *MDC1*.

**Additional file 9: Fig. S9:** Kaplan–Meier analysis of the association between relapse free survival and the mRNA expression.

**Additional file 10: Fig. S10:** Original blots.

**Additional file 11: Table S1:** Sequence information for miR-22-3p mimic and control mimic.

**Additional file 12: Table S2:** Sequence information for guide RNAs used for *AP4* deletion.

**Additional file 13: Table S3:** List of Antibodies.

**Additional file 14: Table S4:** Oligonucleotides used for qPCR.

**Additional file 15: Table S5:** Oligonucleotides used for qChIP.

**Additional file 16: Table S6:** Oligonucleotides used for reporter plasmids.




Figure S1

**Fig. S1: AP4 inactivation induces senescence and apoptosis in CRC cells.** **A** AP4 detection by Western blot analysis. β-actin served as a loading control. **B** Phase contrast images of the indicated cell lines. Scale bars: 50 μm. **C** Colony formation assays of AP4 WT and KO single cell clones obtained from DLD-1 and SW480 cells. Three independent clones were analyzed. **D** Detection of senescent cells using pH6 β-gal staining after 48 hours of transfection. Quantification of a total of 120 cells in 3 fields. Scale bars: 100 μm. **E** Quantification of apoptotic cells by Annexin V / PI detection 48 hours after transfection in the indicated cells (left panel). The flow charts of DLD-1 and SW480 cells with indicated transfections are presented in the right panel.

**F** MTT assay results of indicated cell lines 72 hours after seeding into a 96-well plate.  
**G** Proliferation was determined by impedance measurement. In panels **D-G** the mean  $\pm$  SD (n = 3) is provided. \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001, \*\*\*\*: p < 0.0001.




Figure S2

**Fig. S2: AP4 inactivation induces DNA damage in CRC cells.** **A** Detection of  $\gamma$ H2AX foci. Quantification of a total of 100 cells in 5 fields. Scale bars: 20  $\mu$ m. **B** Western blot analysis of  $\gamma$ H2AX 48 hours after transfection in the indicated cells. **C** Comet assay and quantification of DNA tail moment of a total of 150 cells in 10 fields. Scale bars: 20  $\mu$ m. **D** Western blot analysis 48 hours after transfection of c-MYC-specific siRNA. **E** FACS analysis of DLD-1/SW480 AP4 WT/KO pRTR-c-MYC-VSV pools. Pools with more than 80% GFP-positive cells were selected. **F**  $\gamma$ H2AX detection after c-MYC induction by DOX for indicated durations. Quantification of a total of 100 cells in 5 fields. Scale bars: 20  $\mu$ m. In panels **A** the mean  $\pm$  SD (n = 5), **C** the mean  $\pm$  SD (n = 10) and **F** the mean  $\pm$  SD (n = 5) are provided. \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001.




Figure S3

**Fig. S3: AP4 directly represses *MIR22HG*.** **A** qPCR analysis of *MIR22HG* and *p21* in the indicated clones of SW480 cells. **B** qPCR analysis of miR-22-3p expression (left panel) and nascent *MIR22HG* mRNA (right panel) in the indicated cells. **C** Western blot analysis of MYC-VSV and AP4 expression after c-MYC induction by DOX for indicated durations. **D** qPCR analysis of *MIR22HG* (left panel) and miR-22-3p (right panel) after c-MYC induction by DOX for indicated durations. **E** qPCR analysis of nascent *MIR22HG* mRNA 48 hours after c-MYC induction by DOX. **F** qPCR analysis of *SNAI1* (left panel) and *p21* (right panel) after c-MYC induction by DOX for indicated durations. **G** qPCR analysis of *MIR22HG* 48 hours after transfection. **H** β-gal detection at pH 6 48 hours after transfection. Quantification of a total of 120 cells in 3 fields. Scale bars: 50 μm. In panels **A-B**, **D-H** the mean ± SD (n = 3) is provided with \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001.




Figure S4

**Fig. S4: MDC1 is directly and indirectly regulated by AP4.** **A** qPCR analysis of *MDC1* expression. **B** Western blot analysis. **C** qPCR analysis 48 hours after transfection. **D** Western blot analysis 48 hours after transfection. **E** MDC1 foci detection in untreated cells. Quantification of a total of 120 cells in 3 fields. Scale bars: 20  $\mu$ m. **F** qPCR analysis of nascent *MDC1* mRNA in the indicated cell lines. **G** qPCR analysis of *MDC1* 48 hours after transfections. **H** Western blot analysis 48 hours after transfection. **I** qPCR analysis of nascent *MDC1* mRNA 48 hours after c-MYC induction by DOX. **J** Western blot analysis after induction of c-MYC by DOX for the indicated periods. In panels **A**, **C**, **E-G** and **I** the mean  $\pm$  SD ( $n = 3$ ) is provided with \*:  $p < 0.05$ , \*\*:  $p < 0.01$ , \*\*\*:  $p < 0.001$ .






Figure S5

**Fig. S5: MDC1 mediates effects of AP4 on DNA damage and senescence. A** Detection of MDC1 and  $\gamma$ H2AX foci by immunocytochemistry 48 hours after silencing *MDC1*. Scale bars: 20  $\mu$ m. Quantification of a total of 120 cells in 3 fields. **B** MDC1 and  $\gamma$ H2AX foci were detected by immunocytochemistry 48 hours after ectopic expression of MDC1. Scale bars: 20  $\mu$ m. Quantification of a total of 120 cells in 3 fields. **C**  $\beta$ -gal staining 48 hours after silencing or ectopic expression of MDC1, respectively.

Quantification of a total of 120 cells in 3 fields. Scale bars: 50  $\mu$ m. **D** MTT assay results 48 hours after silencing *MDC1*. **E** MTT assay results 48 hours after ectopic expressing *MDC1*. Detection of **F**  $\gamma$ H2AX foci by immunocytochemistry, **G**  $\beta$ -gal staining and **H** comet assay in DLD-1 *AP4* WT1 cells 48 hours after transfection. Quantification of DNA tail moment of a total of 150 cells in 10 fields. In panel **A-E**, the mean  $\pm$  SD (n = 3), in panel **F-G**, the mean  $\pm$  SD (n = 5) and in panel **H**, the mean  $\pm$  SD (n = 10) are provided with \*\*: p < 0.01, \*\*\*: p < 0.001, \*\*\*\*: p < 0.0001.






Figure S6

**Fig. S6: MDC1 mediates effects of AP4 on chromosomal instability and HR. A** Examples and quantification of micronuclei after DAPI staining. Quantification of a total of 50 cells in 3 fields. Scale bars: 20  $\mu$ m. **B** Kinetic evaluation of micronucleus formation 48 hours after transfection with the indicated oligonucleotides or vectors. **C** The indicated cells were co-transfected with pDR-GFP, pCBAScel plasmids. A pcDNA-mCherry plasmid was also co-transfected as a control of transfection efficiency. The percentage of cells expressing GFP among mCherry-positive cells was measured by flow cytometry 72 hours after transfection. **D-G** The percentage of the indicated cells expressing GFP was measured by flow cytometry after 72 hours of transfections with the indicated plasmids or oligonucleotides. In panels **A-G**, the mean  $\pm$  SD (n = 3) is provided with \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001.




Figure S7

**Fig. S7: AP4 confers resistance towards Etoposide via MDC1.** **A** Immunocytochemistry detection of MDC1 and  $\gamma$ H2AX foci 12 hours after addition of 20  $\mu$ M Etoposide. Quantification of a total of 120 cells in 3 fields. Scale bars: 50  $\mu$ m. **B** MTT assay results 12 hours after 20  $\mu$ M Etoposide treatment. MTT assay results of cells transfected with **C** the indicated oligonucleotides or **D** expression plasmids for 48 hours and then subjected to treatment with Etoposide for another 12 hours. In panels **A-D** the mean  $\pm$  SD (n = 3) is provided with \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001.




Figure S8

**Fig. S8: AP4 confers resistance towards 5-FU via MDC1.** **A** The indicated cells were treated with increasing concentrations of 5-FU for 48 hours. Then the  $IC_{50}$  was determined by an MTT assay. **B-E** The indicated cells were transfected with indicated oligonucleotides for 48 hours and subsequently treated with increasing concentrations

of 5-FU for another 48 hours. After treatments, the IC<sub>50</sub> was determined by an MTT assay. **F-I** Colony formation assay of the indicated cells transfected with the indicated oligonucleotides or plasmids for 48 hours and then subjected to treatment with 10 μM 5-FU for another 48 hours. For the last 48 hours fresh DOX was added. After treatments, cells were cultured for 3 weeks. In panels **A-I**, the mean ± SD (n = 3) is provided with \*: p < 0.05, \*\*: p < 0.01, \*\*\*: p < 0.001.





Figure S9


**Fig. S9: Kaplan–Meier analysis of the association between relapse free survival and *c-MYC*, *AP4*, *MIR22HG* and *MDC1* mRNA expression.** Analysis of **A** *c-MYC*, **B** *AP4*, **C** *MIR22HG* and **D** *MDC1* in patients that received chemotherapy (n = 87) represented in the GSE14333 dataset. The significance was calculated with the log-rank test. Below the graphs, the number of patients at risk with high or low expression of the indicated mRNA at the respective time point is provided. HR, hazard ratio.

**Fig. S10: Original blots.**


Uncropped gel for Figure 1B and S1A




Uncropped gel for Figure 1I and S2B




Uncropped gel for Figure 1K and S2D




uncropped gel of Fig 3B and S4B




uncropped gel of Fig 3E and S4D





uncropped gel of Fig 4E and S4H




uncropped gel of Fig 4F



uncropped gel of Fig 4H and S4J




uncropped gel of Fig 9F





Uncropped gel for Figure S3C



**Table S1: Sequence information for miR-22-3p mimic and control mimic.**

	Sequence information (5'-3')
hsa-miR-22-3p mimic	AAGCUGCCAGUUGAAGAACUGU
Control mimic	UCACCGGGUGUAAAUCAGCUUG

**Table S2: Sequence information for guide RNAs used for AP4 deletion.**

	Sequence information (5'-3')
Guide RNA 1 Forward	CACCGACCAGGAGCGGCGGATTCGG
Guide RNA 1 Reverse	AAACCCGAATCCGCCGCTCCTGGTC
Guide RNA 2 Forward	CACCGCGTCTCCGCTCGTTGCTGT
Guide RNA 2 Reverse	AAACACAGCAACGAGCGGAGACGCC
Guide RNA 3 Forward	CACCGCGCATGCAGAGCATCAACGC
Guide RNA 3 Reverse	AAACGCGTTGATGCTCTGCATGCGC

**Table S3: List of Antibodies.**

Epitope	Species	Catalog No.	Company	Use	Dilution	Source
<b>Primary antibodies</b>						
$\alpha$ -tubulin	Human	# T-9026	Sigma-Aldrich	WB	1:1000	mouse
$\beta$ -actin	Human	# A2066	Sigma-Aldrich	WB	1:1000	rabbit
VSV	Human	# V4888	Sigma-Aldrich	WB	1:7500	rabbit
TFAP4	Human	# MCA4993Z	AbD Serotec	WB; ChIP	1:1000; 3 $\mu$ g	mouse
MDC-1	Human	# NB100-397	NOVUS	WB/IF	1:1000	rabbit
Mdc-1	Mouse	# ab217528	Abcam	IHC	1:400	rabbit
$\gamma$ -H2AX	Human	# JBW301	Sigma-Aldrich	IF	1:1000	mouse
$\gamma$ -H2ax	Mouse	# 9718	Cell Signaling Technology	IHC	1:500	rabbit
p16 (M-156)	Mouse	# sc-1207	Santa Cruz	IHC	1:100	rabbit
Ki67	Mouse	# E0468	Dako	IHC	1:500	rat
F-actin	N.A.	# A12379	Thermo Fisher	IF	1:50	Alexa Fluor® 488 conjugated
<b>Secondary antibodies</b>						
Anti-mouse HRP	N.A.	# W4021	Promega	WB	1:10,000	goat
Anti-rabbit HRP	N.A.	# A0545	Sigma-Aldrich	WB	1:10,000	goat
Alexa Fluor Plus 555	N.A.	# A32727	Thermo Fisher	IF	1:1000	goat
Alexa Fluor Plus 488	N.A.	# A32731	Thermo Fisher	IF	1:1000	goat

**Table S4: Oligonucleotides used for qPCR.**

mRNA	Forward (5'-3')	Reverse (5'-3')
<i>GAPDH</i>	TGTTGCCATCAATGACCCCTT	CTCCACGACGTA CTACTCAGCG
<i>MDC1</i>	TGCTCTTACAGGAGTGGTG	GGGCACACAGGAACTTGACT
<i>AP4</i>	GCAGGCAATCCAGCACAT	GGAGGCGGTGTCAGAGGT
<i>c-MYC</i>	CTTCTCTCCGTCCTCGGATTCT	GAAGGTGATCCAGACTCTGACCTT
<i>β-actin</i>	TGACATTAAGGAGAAGCTGTGCTAC	GAGTTGAAGGTAGTTTCGTGGATG
<i>MIR22HG</i>	TTTGCAATAGGGGATTGCTT	TTTAATGTCTGCGCGGTACTC
<i>p21</i>	GGCGGCAGACCAGCATGACAGATT	GCAGGGGGCGGCCAGGGTAT
<i>SNAI1</i>	GCACATCCGAAGCCACAC	GGAGAAGGTCCGAGCACAC
<i>mmu-Ap4</i>	TCAAGCGCTTTATCCAGGAG	CAATGCCCTCATCCTTGTCT
<i>mmu-Mdc1</i>	CCACAAGAGCCAGGACCTTC	TGTAGCCAAGACTTCCAAGG

**Table S5: Oligonucleotides used for qChIP.**

Gene	Forward (5'-3')	Reverse (5'-3')
<i>MIR22HG</i> (site A)	AGGGGGAGCAAATCACTGCG	CCGTGCATTTCGAGCTCGTG
<i>MIR22HG</i> (site B)	TGATGAGGCTGGAGGGTG	GGAGGGTAAGCAAGGAGGA
<i>MIR22HG</i> (site C)	AGGTCGGAGGTTGAGGAA	GTTGAGGCAGGCTGGAAG
<i>MDC1</i> (site A and B)	GACAACCCACTACCGCTTGC	AAAGGCGCTCTGGCCTTACC
<i>MDC1</i> (site C)	GAGATGACTTGTGGAATAGGAGGTAG	CCTTCCGGGACCTACCTCAG
<i>SNAI1</i>	GGAGTACTTAAGGGAGTTGGCGG	GAACCACTCGCTAGGCCGT
<i>16q22</i>	CTACTCACTTATCCATCCAGGCTAC	ATTTACACACTCAGACATCACAG

**Table S6: Oligonucleotides used for reporter plasmids.**

Oligo	Forward (5'-3')	Reverse (5'-3')
<i>MDC1</i> 3'-UTR	AAACTAGTGA ACTCCACTACCCTTTTC CCTC	GGCTGCAGTAAGGCACAGAGTGA ATATTTATTTATCA
<i>miR-22-3p</i> $\Delta$ SMS	TCATGCTCAGATGTCATAAGATCTTTA GCCAGACTGTTGC	GCAACAGTCTGGCTAAAGATCTTA TGACATCTGAGCATGA
<i>miR-22-3p</i> antisense	AATTCACAGTTCTTCAACTGGCAGCTT CTGCA	GTGTCAAGAAGTTGACCGTCGAA G